ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report)’s stock price dropped 3.9% during trading on Friday . The company traded as low as $16.69 and last traded at $16.72. Approximately 18,563 shares traded hands during trading, a decline of 87% from the average daily volume of 138,573 shares. The stock had previously closed at $17.40.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of ArriVent BioPharma in a report on Thursday, June 6th.
View Our Latest Report on ArriVent BioPharma
ArriVent BioPharma Trading Up 6.6 %
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.14. As a group, equities analysts anticipate that ArriVent BioPharma, Inc. will post -3.07 EPS for the current year.
Institutional Investors Weigh In On ArriVent BioPharma
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new stake in shares of ArriVent BioPharma in the 1st quarter valued at about $83,000. Vanguard Group Inc. bought a new stake in shares of ArriVent BioPharma in the 1st quarter valued at about $11,586,000. American International Group Inc. bought a new stake in shares of ArriVent BioPharma in the 1st quarter valued at about $87,000. Altitude Crest Partners Inc. bought a new stake in shares of ArriVent BioPharma in the 1st quarter valued at about $9,922,000. Finally, Hhlr Advisors LTD. bought a new stake in shares of ArriVent BioPharma in the 1st quarter valued at about $70,174,000. 9.48% of the stock is owned by institutional investors.
About ArriVent BioPharma
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Further Reading
- Five stocks we like better than ArriVent BioPharma
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Stock Dividend Cuts Happen Are You Ready?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- 3 Tickers Leading a Meme Stock Revival
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
